Brian Park on Muck Rack

Brian Park

New York
As seen in: Color Research & Application, Drug and Therapeutics Bulletin, MDPI, The New Yorker, JAMA (The Journal of the American Medical Association), VentureBeat, Medscape, STAT, Annals of Internal Medicine, JD Supra and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brian

Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Investigational Gene Therapy for Parkinson Disease Gets Fast Track Status

|
By Brian Park
| Neurology Advisor Verified
The Food and Drug Administration (FDA) has granted Fast Track designation to AB-1005 for the treatment of moderate Parkinson disease. AB-1005 is an investigational gene therapy based on adeno-associated viral vector serotype 2 containing the human glial cell line-derived neurotrophic factor (GDNF) transgene.
Open in Who Shared Issue with article?

Prefilled Syringe Formulation of Vabysmo Gets FDA Approval

|
By Brian Park
| Ophthalmology Advisor Verified
The Food and Drug Administration (FDA) has approved a new 6mg single-dose prefilled syringe for Vabysmo® (faricimab-svoa). Prior to this approval, Vabysmo had only been available in a single-dose vial. Vabysmo, a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor, is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).
Open in Who Shared Issue with article?

Brexpiprazole Plus Sertraline Under Review for Post-Traumatic Stress Disorder

|
By Brian Park
| Psychiatry Advisor Verified
The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD).
Open in Who Shared Issue with article?
See all 5,093 licensed articles (5,094 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified